On March 16, 2017 National Institutes of Biomedical Innovation, Health and Nutrition (Director General: Yoshihiro Yoneda; Ibaraki-shi, Osaka; hereinafter "NIBIOHN"), Daiichi Sankyo Company, Limited (Representative Director, President and CEO: George Nakayama; head office: Chuo-ku, Tokyo; hereinafter "Daiichi Sankyo"), and Mitsubishi UFJ Capital Co., Ltd. (President: Muneki Handa; head office: Chuo-ku, Tokyo; hereinafter "Mitsubishi UFJ Capital") reported that they will launch open innovation research ("the research") on new cancer immunotherapy (Press release, Daiichi Sankyo, MAR 15, 2017, View Source [SID1234518205]).

To carry out the research, a new company called OiDE Adjubilee, Inc. (head office: Chuo-ku, Tokyo; hereinafter "Adjubilee") was established and wholly funded by the OiDE Fund Investment Limited Partnership ("OiDE Fund"), operated by Mitsubishi UFJ Capital.

If the goals of the two-year joint research are achieved, Daiichi Sankyo will purchase all Adjubilee stock in order to continue research and development of the new cancer immunotherapy on its own, paying sales royalties to NIBIOHN following a successful product launch.

This research into new cancer immunotherapy is the second OiDE Fund investment, and Daiichi Sankyo and Mitsubishi UFJ Capital plan to continue to promote open innovation activities to develop new drug discovery platforms using the OiDE Fund.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!